Symbols / PRPH
PRPH Chart
About
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 710.55K |
| Enterprise Value | 7.98M | Income | -49.56M | Sales | 5.05M |
| Book/sh | 1.65 | Cash/sh | 0.09 | Dividend Yield | — |
| Payout | 0.00% | Employees | 96 | IPO | — |
| P/E | — | Forward P/E | 0.31 | PEG | — |
| P/S | 0.14 | P/B | 0.09 | P/C | — |
| EV/EBITDA | -0.33 | EV/Sales | 1.58 | Quick Ratio | 0.07 |
| Current Ratio | 0.14 | Debt/Eq | 112.00 | LT Debt/Eq | — |
| EPS (ttm) | -19.80 | EPS next Y | 0.48 | EPS Growth | — |
| Revenue Growth | -37.60% | Earnings | 2026-03-30 | ROA | -23.50% |
| ROE | -220.34% | ROIC | — | Gross Margin | 19.52% |
| Oper. Margin | -5.40% | Profit Margin | 0.00% | Shs Outstand | 4.74M |
| Shs Float | 4.32M | Short Float | 0.71% | Short Ratio | 0.08 |
| Short Interest | — | 52W High | 6.70 | 52W Low | 0.12 |
| Beta | -0.51 | Avg Volume | 1.21M | Volume | 11.91K |
| Target Price | — | Recom | None | Prev Close | $0.15 |
| Price | $0.15 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.15
Latest analyst target
3. DCF / Fair value
$193.08
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.15
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-02-21 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-11-10 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2023-06-02 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2023-05-12 | main | HC Wainwright & Co. | Buy → Buy | $14 |
| 2023-03-08 | reit | HC Wainwright & Co. | — → Buy | $15 |
| 2023-02-23 | reit | HC Wainwright & Co. | — → Buy | $15 |
| 2023-02-16 | reit | HC Wainwright & Co. | — → Buy | $15 |
| 2023-02-07 | reit | HC Wainwright & Co. | — → Buy | $15 |
| 2022-11-11 | main | HC Wainwright & Co. | — → Buy | $15 |
| 2022-05-17 | main | HC Wainwright & Co. | — → Buy | $14 |
| 2022-03-31 | main | HC Wainwright & Co. | — → Buy | $16 |
| 2022-01-14 | main | HC Wainwright & Co. | — → Buy | $15 |
| 2021-12-20 | init | HC Wainwright & Co. | — → Buy | $12 |
| 2021-10-13 | down | Dawson James | Buy → Neutral | — |
- ProPhase’s proposed ABL merger could mean cash payout for holders - Stock Titan Fri, 19 Dec 2025 08
- ProPhase Labs Inc (PRPH) Q3 2025 Earnings Call Highlights: Strategic Initiatives and Financial ... - Yahoo Finance Wed, 26 Nov 2025 08
- ProPhase Labs (PRPH) Stock News: Reverse Merger LOI With ABL, 1-for-10 Reverse Split Takes Effect Dec. 22, 2025 - TechStock² Mon, 22 Dec 2025 08
- ProPhase Labs Explores Strategic Initiatives to Unlock Company Value Amidst Key Developments in Crown Medical and BE-Smartâ„¢ Commercialization - Quiver Quantitative Wed, 19 Nov 2025 08
- Why Is Prophase Labs Stock (PRPH) Up Today? - TipRanks Fri, 19 Dec 2025 08
- ProPhase Labs stock soars after announcing reverse merger with ABL - Investing.com Fri, 19 Dec 2025 08
- ProPhase Labs (NASDAQ: PRPH) to Detail BE-Smart Cancer Test, $7–14B Market Opportunity - Stock Titan Wed, 26 Nov 2025 08
- ProPhase Labs Inc (PRPH) Q2 2025 Earnings Call Highlights: Strategic Moves and Future Prospects - Yahoo Finance Fri, 15 Aug 2025 07
- ProPhase Labs Stockholders Approve Strategic Initiatives and Increase Authorized Shares at Special Meeting - Quiver Quantitative Fri, 12 Sep 2025 07
- Prophase Labs Implements Reverse Stock Split - TipRanks Fri, 12 Dec 2025 08
- Two lab companies explore reverse merger that could reshape ownership - Stock Titan Fri, 19 Dec 2025 08
- ProPhase Labs (NASDAQ: PRPH) engages RedChip to lead investor relations: $50M target - Stock Titan ue, 28 Oct 2025 07
- How one lab swapped $3.3M of debt for shares, jolting its stock price - Stock Titan Mon, 05 Jan 2026 08
- $50M Medical Collections Expected: ProPhase Labs Advances Crypto Strategy While Developing Cancer Test - Stock Titan Mon, 22 Sep 2025 07
- ProPhase chases $50M from insurers as 50 COVID test claims near deals - Stock Titan Mon, 26 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -69.93K | 0.00 | -14.75K | -1.08M |
| TaxRateForCalcs | 0.21 | 0.27 | 0.19 | 0.27 |
| NormalizedEBITDA | -32.00M | -14.66M | 28.81M | 14.01M |
| TotalUnusualItems | -333.00K | 0.00 | -76.00K | -3.99M |
| TotalUnusualItemsExcludingGoodwill | -333.00K | 0.00 | -76.00K | -3.99M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -49.52M | -16.38M | 18.46M | 6.27M |
| ReconciledDepreciation | 6.64M | 6.47M | 5.06M | 3.56M |
| ReconciledCostOfRevenue | 6.92M | 19.43M | 51.99M | 37.05M |
| EBITDA | -32.34M | -14.66M | 28.73M | 10.02M |
| EBIT | -38.98M | -21.13M | 23.67M | 6.45M |
| NetInterestIncome | -3.35M | -1.19M | -611.00K | -506.00K |
| InterestExpense | 3.35M | 1.27M | 764.00K | 1.15M |
| InterestIncome | 0.00 | 78.00K | 153.00K | 642.00K |
| NormalizedIncome | -49.26M | -16.38M | 18.52M | 9.19M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -53.36M | -16.78M | 18.46M | 6.27M |
| TotalExpenses | 45.40M | 56.20M | 99.05M | 69.24M |
| TotalOperatingIncomeAsReported | -38.63M | -21.22M | 23.59M | 9.80M |
| DilutedAverageShares | 2.99M | 1.72M | 1.87M | 1.84M |
| BasicAverageShares | 2.99M | 1.72M | 1.58M | 1.52M |
| DilutedEPS | -26.10 | -9.80 | 10.20 | 4.00 |
| BasicEPS | -26.10 | -9.80 | 11.70 | 4.10 |
| DilutedNIAvailtoComStockholders | -53.36M | -16.78M | 19.09M | 7.27M |
| AverageDilutionEarnings | 0.00 | 632.00K | 1.00M | |
| NetIncomeCommonStockholders | -53.36M | -16.78M | 18.46M | 6.27M |
| NetIncome | -53.36M | -16.78M | 18.46M | 6.27M |
| NetIncomeIncludingNoncontrollingInterests | -53.36M | -16.78M | 18.46M | 6.27M |
| NetIncomeDiscontinuousOperations | -3.84M | -402.00K | 0.00 | |
| NetIncomeContinuousOperations | -49.52M | -16.38M | 18.46M | 6.27M |
| TaxProvision | 7.20M | -6.02M | 4.45M | -968.00K |
| PretaxIncome | -42.33M | -22.40M | 22.91M | 5.30M |
| OtherIncomeExpense | -351.00K | 10.00K | -76.00K | -3.99M |
| OtherNonOperatingIncomeExpenses | -18.00K | 10.00K | ||
| SpecialIncomeCharges | -333.00K | 0.00 | 0.00 | -3.75M |
| GainOnSaleOfPPE | 0.00 | |||
| OtherSpecialCharges | 333.00K | |||
| WriteOff | 0.00 | 3.75M | ||
| GainOnSaleOfSecurity | -76.00K | -240.00K | ||
| NetNonOperatingInterestIncomeExpense | -3.35M | -1.19M | -611.00K | -506.00K |
| InterestExpenseNonOperating | 3.35M | 1.27M | 764.00K | 1.15M |
| InterestIncomeNonOperating | 0.00 | 78.00K | 153.00K | 642.00K |
| OperatingIncome | -38.63M | -21.22M | 23.59M | 9.80M |
| OperatingExpense | 38.48M | 36.78M | 47.06M | 32.19M |
| OtherOperatingExpenses | 1.93M | 12.02M | 9.17M | |
| ResearchAndDevelopment | 594.00K | 1.40M | 652.00K | 520.00K |
| SellingGeneralAndAdministration | 37.88M | 33.44M | 34.38M | 22.49M |
| GeneralAndAdministrativeExpense | 37.88M | 33.44M | 34.38M | 22.49M |
| OtherGandA | 37.88M | 33.44M | 34.38M | 22.49M |
| GrossProfit | -150.00K | 15.56M | 70.65M | 41.99M |
| CostOfRevenue | 6.92M | 19.43M | 51.99M | 37.05M |
| TotalRevenue | 6.77M | 34.98M | 122.65M | 79.04M |
| OperatingRevenue | 6.77M | 34.98M | 122.65M | 79.04M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 1.29M | 1.89M | 1.81M | 1.68M |
| OrdinarySharesNumber | 2.99M | 1.80M | 1.62M | 1.55M |
| ShareIssued | 4.28M | 3.70M | 3.43M | 3.23M |
| NetDebt | 14.18M | 5.72M | 1.63M | |
| TotalDebt | 24.57M | 18.46M | 6.96M | 14.90M |
| TangibleBookValue | -7.63M | 31.82M | 49.45M | 42.07M |
| InvestedCapital | 22.21M | 56.72M | 66.03M | 68.67M |
| WorkingCapital | -1.50M | 26.73M | 44.76M | 45.79M |
| NetTangibleAssets | -7.63M | 31.82M | 49.45M | 42.07M |
| CapitalLeaseObligations | 9.71M | 11.12M | 4.56M | 4.86M |
| CommonStockEquity | 7.35M | 49.38M | 63.63M | 58.63M |
| TotalCapitalization | 19.00M | 56.72M | 66.03M | 68.67M |
| TotalEquityGrossMinorityInterest | 7.35M | 49.38M | 63.63M | 58.63M |
| StockholdersEquity | 7.35M | 49.38M | 63.63M | 58.63M |
| GainsLossesNotAffectingRetainedEarnings | -198.00K | -300.00K | 757.00K | -175.00K |
| OtherEquityAdjustments | -198.00K | -300.00K | 757.00K | -175.00K |
| TreasuryStock | 64.00M | 64.00M | 58.03M | 48.41M |
| RetainedEarnings | -58.39M | -5.03M | 11.75M | 2.64M |
| AdditionalPaidInCapital | 129.92M | 118.69M | 109.14M | 104.55M |
| CapitalStock | 23.00K | 18.00K | 16.00K | 16.00K |
| CommonStock | 23.00K | 18.00K | 16.00K | 16.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 55.85M | 42.54M | 24.02M | 30.67M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 23.71M | 21.69M | 7.94M | 15.14M |
| LiabilitiesHeldforSaleNonCurrent | 2.92M | 2.92M | ||
| TradeandOtherPayablesNonCurrent | 2.00M | 2.00M | 0.00 | |
| NonCurrentDeferredLiabilities | 784.00K | 1.10M | 1.28M | 905.00K |
| NonCurrentDeferredRevenue | 784.00K | 1.10M | 1.06M | 905.00K |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 224.00K | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 18.00M | 15.66M | 6.66M | 14.24M |
| LongTermCapitalLeaseObligation | 6.35M | 8.33M | 4.26M | 4.20M |
| LongTermDebt | 11.65M | 7.33M | 2.40M | 10.04M |
| CurrentLiabilities | 32.13M | 20.86M | 16.07M | 15.52M |
| OtherCurrentLiabilities | 5.87M | 835.00K | ||
| CurrentDeferredLiabilities | 1.70M | 2.38M | 2.50M | 2.03M |
| CurrentDeferredRevenue | 1.70M | 2.38M | 2.50M | 2.03M |
| CurrentDebtAndCapitalLeaseObligation | 6.57M | 2.79M | 301.00K | 663.00K |
| CurrentCapitalLeaseObligation | 3.36M | 2.79M | 301.00K | 663.00K |
| CurrentDebt | 3.21M | |||
| OtherCurrentBorrowings | 3.21M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 63.00K | 1.03M | 50.00K | 60.00K |
| PayablesAndAccruedExpenses | 17.94M | 13.81M | 13.22M | 12.77M |
| CurrentAccruedExpenses | 2.23M | 1.89M | 3.13M | 4.43M |
| Payables | 15.70M | 11.92M | 10.10M | 8.34M |
| TotalTaxPayable | 1.99M | 3.28M | 4.19M | 1.31M |
| IncomeTaxPayable | 1.99M | 3.28M | 4.19M | 1.31M |
| AccountsPayable | 13.72M | 8.64M | 5.91M | 7.03M |
| TotalAssets | 63.20M | 91.93M | 87.65M | 89.30M |
| TotalNonCurrentAssets | 32.56M | 44.34M | 26.82M | 27.98M |
| OtherNonCurrentAssets | 5.75M | 3.73M | 1.16M | 608.00K |
| NonCurrentPrepaidAssets | 217.00K | 832.00K | 121.00K | 460.00K |
| NonCurrentDeferredAssets | 0.00 | 7.31M | 0.00 | |
| NonCurrentDeferredTaxesAssets | 0.00 | 7.31M | 0.00 | |
| NonCurrentNoteReceivables | 0.00 | |||
| GoodwillAndOtherIntangibleAssets | 14.98M | 17.56M | 14.18M | 16.56M |
| OtherIntangibleAssets | 9.75M | 12.33M | 8.47M | 10.85M |
| Goodwill | 5.23M | 5.23M | 5.71M | 5.71M |
| NetPPE | 11.62M | 14.90M | 11.35M | 10.35M |
| AccumulatedDepreciation | -8.98M | -6.10M | -8.44M | -6.88M |
| GrossPPE | 20.60M | 21.00M | 19.79M | 17.23M |
| Leases | 1.24M | 374.00K | 0.00 | |
| OtherProperties | 15.93M | 17.24M | 9.85M | 8.73M |
| MachineryFurnitureEquipment | 3.43M | 3.39M | 7.86M | 6.42M |
| BuildingsAndImprovements | 1.75M | 1.73M | 1.73M | |
| LandAndImprovements | 352.00K | 352.00K | 352.00K | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 30.64M | 47.59M | 60.83M | 61.32M |
| OtherCurrentAssets | 2.62M | 1.96M | 2.37M | 1.50M |
| AssetsHeldForSaleCurrent | 6.14M | 2.79M | ||
| RestrictedCash | 540.00K | 0.00 | 250.00K | |
| PrepaidAssets | 1.50M | |||
| Inventory | 1.14M | 2.29M | 3.98M | 4.60M |
| InventoriesAdjustmentsAllowances | -8.00K | -219.00K | -512.00K | -435.00K |
| FinishedGoods | 375.00K | 1.32M | 356.00K | 272.00K |
| WorkInProcess | 65.00K | 119.00K | 754.00K | 260.00K |
| RawMaterials | 711.00K | 1.07M | 3.38M | 4.50M |
| Receivables | 20.06M | 35.81M | 37.05M | 37.71M |
| ReceivablesAdjustmentsAllowances | -14.84M | -3.86M | -3.14M | -3.90M |
| OtherReceivables | 2.63M | 23.09M | ||
| AccountsReceivable | 34.90M | 39.68M | 37.57M | 18.52M |
| CashCashEquivalentsAndShortTermInvestments | 678.00K | 4.74M | 17.44M | 17.26M |
| OtherShortTermInvestments | 0.00 | 3.13M | 8.33M | 8.86M |
| CashAndCashEquivalents | 678.00K | 1.61M | 9.11M | 8.41M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -18.44M | -13.97M | 24.63M | -17.85M |
| RepurchaseOfCapitalStock | 0.00 | -5.97M | -9.63M | -917.00K |
| RepaymentOfDebt | -4.25M | 0.00 | -7.04M | -45.00K |
| IssuanceOfDebt | 9.86M | 7.60M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 7.59M | 0.00 | 0.00 | 40.63M |
| CapitalExpenditure | -906.00K | -2.08M | -3.92M | -4.23M |
| InterestPaidSupplementalData | 3.10M | 932.00K | 763.00K | 1.00M |
| IncomeTaxPaidSupplementalData | 1.13M | 3.00M | 1.70M | 0.00 |
| EndCashPosition | 678.00K | 1.61M | 9.11M | 8.66M |
| BeginningCashPosition | 1.61M | 9.11M | 8.66M | 6.82M |
| ChangesInCash | -931.00K | -7.50M | 451.00K | 1.84M |
| FinancingCashFlow | 14.19M | 5.76M | -26.02M | 35.13M |
| CashFromDiscontinuedFinancingActivities | 978.00K | 2.92M | ||
| CashFlowFromContinuingFinancingActivities | 13.21M | 2.83M | -26.02M | 35.13M |
| ProceedsFromStockOptionExercised | 0.00 | 1.20M | 0.00 | |
| CashDividendsPaid | 0.00 | -9.35M | -4.55M | |
| CommonStockDividendPaid | 0.00 | -9.35M | -4.55M | |
| NetCommonStockIssuance | 7.59M | -5.97M | -9.63M | 39.72M |
| CommonStockPayments | 0.00 | -5.97M | -9.63M | -917.00K |
| CommonStockIssuance | 7.59M | 0.00 | 0.00 | 40.63M |
| NetIssuancePaymentsOfDebt | 5.61M | 7.60M | -7.04M | -45.00K |
| NetLongTermDebtIssuance | 5.61M | 7.60M | -7.04M | -45.00K |
| LongTermDebtPayments | -4.25M | 0.00 | -7.04M | -45.00K |
| LongTermDebtIssuance | 9.86M | 7.60M | 0.00 | 0.00 |
| InvestingCashFlow | 2.42M | -1.37M | -2.08M | -19.67M |
| CashFromDiscontinuedInvestingActivities | -275.00K | -1.07M | ||
| CashFlowFromContinuingInvestingActivities | 2.70M | -298.00K | -2.08M | -19.67M |
| NetOtherInvestingChanges | 478.00K | -700.00K | ||
| NetInvestmentPurchaseAndSale | 3.37M | 4.17M | 1.39M | -5.67M |
| SaleOfInvestment | 3.37M | 7.99M | 8.17M | 15.86M |
| PurchaseOfInvestment | 0.00 | -3.82M | -6.78M | -21.53M |
| NetBusinessPurchaseAndSale | 0.00 | -2.43M | 0.00 | -9.07M |
| SaleOfBusiness | 0.00 | 478.00K | ||
| PurchaseOfBusiness | 0.00 | -2.90M | 0.00 | -9.07M |
| NetPPEPurchaseAndSale | 229.00K | 46.00K | 452.00K | 0.00 |
| SaleOfPPE | 229.00K | 46.00K | 452.00K | 0.00 |
| CapitalExpenditureReported | -906.00K | -2.08M | -3.92M | -4.23M |
| OperatingCashFlow | -17.54M | -11.89M | 28.55M | -13.62M |
| CashFromDiscontinuedOperatingActivities | -5.74M | 305.00K | ||
| CashFlowFromContinuingOperatingActivities | -11.80M | -12.19M | 28.55M | -13.62M |
| ChangeInWorkingCapital | 14.89M | -6.72M | -4.34M | -34.62M |
| ChangeInOtherWorkingCapital | 6.15M | -7.70M | 481.00K | 2.61M |
| ChangeInOtherCurrentLiabilities | -1.78M | 456.00K | -724.00K | -2.70M |
| ChangeInOtherCurrentAssets | 853.00K | 0.00 | -555.00K | -368.00K |
| ChangeInPayablesAndAccruedExpense | 3.62M | 1.18M | 871.00K | 4.34M |
| ChangeInAccruedExpense | -156.00K | -770.00K | -886.00K | 1.89M |
| ChangeInPayable | 3.77M | 1.95M | 1.76M | 2.45M |
| ChangeInAccountPayable | 5.07M | 2.86M | -1.12M | 2.45M |
| ChangeInTaxPayable | -1.29M | -911.00K | 2.88M | |
| ChangeInIncomeTaxPayable | -1.29M | -911.00K | 2.88M | |
| ChangeInPrepaidAssets | -45.00K | -216.00K | -617.00K | 1.45M |
| ChangeInInventory | 1.36M | 170.00K | 702.00K | -1.75M |
| ChangeInReceivables | 4.74M | -617.00K | -4.50M | -38.20M |
| ChangesInAccountReceivables | 4.74M | -617.00K | -4.50M | -38.20M |
| OtherNonCashItems | 1.49M | 132.00K | 4.00K | -311.00K |
| StockBasedCompensation | 3.64M | 3.54M | 3.99M | 3.18M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | -174.00K | 240.00K | |
| ProvisionandWriteOffofAssets | 10.81M | 724.00K | -839.00K | 4.13M |
| AssetImpairmentCharge | 0.00 | 91.00K | 6.16M | 3.75M |
| DepreciationAmortizationDepletion | 6.64M | 6.47M | 5.06M | 3.56M |
| DepreciationAndAmortization | 6.64M | 6.47M | 5.06M | 3.56M |
| Depreciation | 6.64M | 6.47M | 5.06M | 3.56M |
| OperatingGainsLosses | 260.00K | -45.00K | 227.00K | 165.00K |
| GainLossOnInvestmentSecurities | 18.00K | -22.00K | 354.00K | 165.00K |
| GainLossOnSaleOfPPE | -91.00K | -23.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -49.52M | -16.38M | 18.46M | 6.27M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PRPH
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|